Loading patent…
AssigneeTrueBinding, Inc.
InventorsDongxu Sun, Catherine A. Gordon, Ksenya Shchors, Yan Wang, Tsung-Huang Tsai, Yew Ann Leong
Estimating the term…
Disclosed herein are methods, antibodies, and compositions for disrupting an interaction between Galectin-3 (Gal3) and viral proteins, such as proteins of the SARS-CoV-2 virus or other coronaviruses, or viral-associated host proteins. Further disclosed herein are methods, medicaments, and compositions for the treatment of a disease or a disorder in a subject, such as the treatment of a viral infection, or treatment of a fibrosis, such as lung fibrosis, that develop as a sequela of a viral infection, or cytokine release syndrome. Further disclosed herein are methods, medicaments, and compositions for the treatment of an inflammatory disease or disorder, such as inflammation of the lungs or systemic lupus erythematosus, which may be associated with neutrophil activity, in a subject. Also disclosed herein are pharmaceutical antibody formulations for the treatment of a disease, such as a coronavirus infection.
An anti-Gal3 antibody or binding fragment comprising (1) a heavy chain variable region comprising a VH-CDR1, a VH-CDR2, and a VH-CDR3;
An anti-Gal3 antibody or binding fragment thereof comprising (1) a heavy chain variable region (VH) and (2) a light chain variable region (VL), wherein
An anti-Gal3 antibody or binding fragment comprising (1) a heavy chain variable region comprising a VH-CDR1, a VH-CDR2, and a VH-CDR3;
Dependencies are inferred from the claim text.